Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing

Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.

NEW YORK, March 9, 2015 /CNW/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that the March 5th presentation from Dr. Roger Crystal, Chief Executive Officer, and Kevin Pollack, Chief Financial Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.

LINK: http://VirtualInvestorConferences.com > red "register/ watch presentations" button

Lightlake's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

Recent Lightlake Highlights:

  • Entered licensing deal with Adapt Pharma Limited subsidiary with respect to opioid overdose reversal treatment that includes potential milestone payments of more than $55 million, plus up to double-digit royalties.
  • Fast Track designation for opioid overdose reversal treatment received from the United States Food and Drug Administration.
  • Commenced trial for opioid overdose reversal treatment with the U.S. National Institute on Drug Abuse, part of the National Institutes of Health

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, and has entered into a licensing deal with a subsidiary of Adapt Pharma Limited. Lightlake also has completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com.

About VirtualInvestorConferences.com

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

SOURCE Lightlake Therapeutics Inc.

For further information: Corporate Contact: Lightlake Therapeutics Inc., Dr. Roger Crystal, CEO, (212) 829-5546, investor.relations@lightlaketherapeutics.com; Investor Relations Contact: Amato and Partners, LLC, admin@amatoandpartners.com; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, bradley.smith@prnewswire.com, http://www.lightlaketherapeutics.com

Organization Profile

Lightlake Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890